Helus Pharma prices $50M share offering at $4.85 per share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Helus Pharma™ Announces US$50 Million Underwritten Offering
June 24, 2026 6:01 AM EDTNEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the Company or Helus Pharma), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (NSAs), is pleased to announce the pricing of an underwritten offering of 10,309,280 common shares in the capital of the Company (the Common Shares) at an offering price of US$4.85 per Common Share, for aggregate gross proceeds of US$50 million (the Offering).
... More